Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT

Key Points

• Dimensional Fund Advisors nearly doubled its stake in Sagimet Biosciences during the first quarter, adding 135,178 shares and bringing its holdings to 271,217 shares, or 0.83% of the company. Institutional investors collectively own 87.86% of SGMT.
• Analyst sentiment remains generally positive: seven analysts rate the stock a Buy, while its consensus rating is “Moderate Buy” with an average price target of $29.17. Citizens JMP raised its target to $29 and Canaccord Genuity lifted its target to $56.
• Insiders sold shares while the company continues to report losses. Recent insider sales totaled 113,646 shares worth about $920,491, and Sagimet reported a quarterly loss of $0.26 per share, slightly below the consensus estimate.

Dimensional Fund Advisors LP grew its position in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 99.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 271,217 shares of the company's stock after acquiring an additional 135,178 shares during the quarter. Dimensional Fund Advisors LP owned 0.83% of Sagimet Biosciences worth $1,415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in shares of Sagimet Biosciences by 819.2% in the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company's stock valued at $29,000 after acquiring an additional 4,391 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Sagimet Biosciences in the 4th quarter worth $30,000. Bank of America Corp DE increased its holdings in Sagimet Biosciences by 81.8% during the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company's stock valued at $76,000 after purchasing an additional 4,473 shares during the period. Virtu Financial LLC bought a new position in shares of Sagimet Biosciences during the fourth quarter valued at approximately $62,000. Finally, Jefferies Financial Group Inc. bought a new position in Sagimet Biosciences in the 3rd quarter worth $95,000. Institutional investors own 87.86% of the company's stock.

Insider Activity

In other news, Director George Kemble sold 20,206 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the sale, the director owned 62,161 shares of the company's stock, valued at $618,501.95. This trade represents a 24.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Happel sold 64,051 shares of the firm's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $497,035.76. Following the completion of the sale, the chief executive officer directly owned 741,570 shares of the company's stock, valued at $5,754,583.20. The trade was a 7.95% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 113,646 shares of company stock worth $920,491. Insiders own 11.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SGMT. Weiss Ratings restated a "sell (d-)" rating on shares of Sagimet Biosciences in a research note on Friday, July 17th. Oppenheimer restated an "outperform" rating on shares of Sagimet Biosciences in a report on Friday, May 1st. Canaccord Genuity Group lifted their price target on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday. Wall Street Zen downgraded Sagimet Biosciences from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Citizens Jmp increased their price target on shares of Sagimet Biosciences from $12.00 to $29.00 and gave the stock a "market outperform" rating in a research report on Friday. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Sagimet Biosciences Stock Performance

NASDAQ SGMT opened at $10.55 on Friday. The company's 50-day simple moving average is $7.51 and its two-hundred day simple moving average is $6.57. The company has a market capitalization of $343.77 million, a price-to-earnings ratio of -8.24 and a beta of 3.37. Sagimet Biosciences Inc. has a one year low of $4.50 and a one year high of $10.60.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.01). Equities analysts expect that Sagimet Biosciences Inc. will post -1.15 earnings per share for the current fiscal year.

Sagimet Biosciences News Summary

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: FDA clears Phase 3 acne study: The FDA accepted Sagimet’s Investigational New Drug application and issued a “Study May Proceed” letter for a U.S. Phase 3 trial of oral, once-daily denifanstat in moderate to severe acne. The trial is expected to begin in the second half of 2026 and enroll approximately 800 patients, including about 450 adolescents. This advances the company’s lead program into a late-stage study and could materially improve its commercial prospects if efficacy and safety are confirmed. FDA Study May Proceed letter and IND clearance
• Positive Sentiment: Citizens JMP raises price target: Citizens JMP increased its target for Sagimet from $12 to $29 and maintained a “Market Outperform” rating. The higher target reflects stronger expectations for denifanstat’s development following the FDA clearance. Citizens JMP price target update
• Positive Sentiment: Additional analyst support: Canaccord Genuity also issued a bullish outlook for SGMT, adding to generally positive Wall Street sentiment around the company’s pipeline and potential future appreciation. Canaccord Genuity Sagimet forecast
• Negative Sentiment: Continued operating losses: Sagimet reported a quarterly loss of $0.26 per share, slightly worse than the $0.25 analyst consensus, while HC Wainwright lowered its fourth-quarter loss estimate to $0.32 per share. The company remains dependent on clinical progress and likely future financing.
• Negative Sentiment: Insider selling: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. Although the sale may be routine, it could temper investor sentiment following the recent rally. George Kemble insider sale

Sagimet Biosciences Profile

Sagimet Biosciences NASDAQ: SGMT is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source